CA
NZ
UK
AU
IND
US
…
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
BioArctic AB is a Swedish biopharmaceutical company focused on R&D of disease‑modifying therapies for neurodegenerative disorders, notably Alzheimer's and Parkinson's disease. Long-term growth drivers include milestone and royalty streams from partnered programs, progress of its clinical pipeline and new licensing deals, which may benefit investors seeking exposure to potential upside from successful development.
Principal risks are clinical and regulatory failure, concentration of revenue risk from partner-dependent royalties and limited internal revenues that could require additional financing and dilute shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1252.44M | -189.52M | 276.49M | -11.17M | -140.51M |
| Net income | 1019.76M | -177.08M | 229.25M | -11.18M | -119.79M |
| Selling general administrative | 194.83M | 93.38M | - | 30.58M | 24.85M |
| Selling and marketing expenses | - | 55.46M | - | - | - |
| Gross profit | 1935.03M | 230.37M | 526.37M | 153.97M | -31.92M |
| Reconciled depreciation | - | 10.72M | 17.44M | 14.18M | 13.04M |
| Ebit | 1364.71M | -229.62M | 276.81M | -10.61M | -139.67M |
| Ebitda | 1377.51M | -211.19M | 295.24M | 4.03M | -126.57M |
| Depreciation and amortization | 12.80M | 18.43M | 18.43M | 14.63M | 13.11M |
| Operating income | 1364.71M | -228.51M | 252.64M | -17.44M | -139.72M |
| Other operating expenses | 629.39M | 485.87M | 363.36M | 236.23M | 163.00M |
| Interest expense | 37.81M | 1.85M | 0.38M | 0.56M | 0.84M |
| Tax provision | 233.26M | -12.44M | 35.65M | 0.01M | -20.72M |
| Interest income | 34.68M | 40.84M | 20.66M | 2.54M | 0.07M |
| Net interest income | -3.22M | 39.00M | 18.94M | 1.78M | -0.98M |
| Income tax expense | 232.68M | -12.44M | 47.24M | 0.01M | -20.72M |
| Total revenue | 1994.10M | 257.35M | 616.00M | 228.29M | 23.15M |
| Total operating expenses | 570.32M | 458.88M | 273.73M | 161.90M | 107.93M |
| Cost of revenue | 59.07M | 26.98M | 89.63M | 74.33M | 55.07M |
| Total other income expense net | -112.28M | 38.99M | 23.85M | 6.17M | -0.79M |
| Net income from continuing ops | 1022.32M | -177.08M | 258.62M | -11.18M | -119.79M |
| Net income applicable to common shares | - | - | - | -11.18M | -119.79M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2568.77M | 1111.68M | 1186.08M | 858.31M | 897.73M |
| Other current assets | 295.78M | 160.55M | 40.95M | 15.45M | -0.00M |
| Total liab | 606.62M | 216.74M | 139.50M | 72.06M | 109.05M |
| Total stockholder equity | 1962.15M | 894.94M | 1046.58M | 786.24M | 788.68M |
| Other current liab | 333.22M | 112.06M | 58.51M | 5.43M | 63.04M |
| Common stock | 1.77M | 1.77M | 1.77M | 786.24M | 1.76M |
| Capital stock | - | 1.77M | 1.77M | 1.76M | 1.76M |
| Retained earnings | - | 305.11M | 462.87M | 217.52M | 225.94M |
| Other liab | - | - | - | - | 0.00M |
| Other assets | - | - | 0.00M | 2.20M | 2.20M |
| Cash | 1037.82M | 512.93M | 611.57M | 805.39M | 848.40M |
| Total current liabilities | 519.47M | 175.66M | 124.97M | 70.88M | 101.27M |
| Current deferred revenue | - | - | 33.76M | - | - |
| Net debt | -965.58M | -458.70M | -606.59M | - | - |
| Short term debt | 15.68M | 13.15M | 2.83M | - | - |
| Short long term debt total | 72.24M | 54.23M | 4.98M | - | - |
| Other stockholder equity | 1960.38M | 587.10M | 580.98M | - | 0.96M |
| Property plant equipment | - | - | - | 35.26M | 33.75M |
| Total current assets | 2480.72M | 1010.66M | 1152.74M | 820.84M | 861.79M |
| Net tangible assets | - | - | - | 786.24M | 788.68M |
| Short term investments | 1147.12M | 265.99M | 500.00M | - | - |
| Net receivables | - | 71.20M | 0.22M | 0.00M | 9.04M |
| Accounts payable | 170.57M | 50.45M | 29.87M | 26.92M | 11.82M |
| Accumulated other comprehensive income | - | 0.96M | 0.96M | - | - |
| Non currrent assets other | 0.00M | 3.44M | 1.65M | - | 0.00M |
| Non current assets total | 88.05M | 101.02M | 33.34M | 37.47M | 35.94M |
| Capital lease obligations | 44.07M | 54.23M | 4.98M | 10.04M | 15.88M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 205.63M | -306.56M | -12.76M | -0.03M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | -892.41M | 205.63M | - | -12.76M | -4.41M |
| Net borrowings | - | - | - | -2.80M | -7.39M |
| Total cash from financing activities | 26.84M | 5.69M | 14.06M | -2.81M | -7.39M |
| Change to operating activities | - | - | - | 24.91M | 0.06M |
| Net income | 1019.76M | -228.51M | 252.64M | -17.44M | -139.72M |
| Change in cash | 612.24M | -98.64M | -193.82M | -43.02M | -151.53M |
| Begin period cash flow | 425.58M | 611.57M | 805.39M | 848.40M | 999.94M |
| End period cash flow | 1037.82M | 512.93M | 611.57M | 805.39M | 848.40M |
| Total cash from operating activities | 1427.48M | -316.33M | 309.69M | -31.64M | -140.46M |
| Issuance of capital stock | - | 6.02M | 14.98M | 5.99M | 0.00M |
| Depreciation | 12.80M | 10.72M | 7.44M | 14.18M | 13.04M |
| Other cashflows from investing activities | -892.41M | 205.63M | - | 0.04M | 0.00M |
| Change to inventory | - | - | -14.41M | - | - |
| Change to account receivables | -64.61M | -105.22M | -11.98M | -0.23M | -0.56M |
| Other cashflows from financing activities | 26.84M | -0.00M | -0.92M | -8.79M | -7.39M |
| Change to netincome | - | - | - | -60.01M | -29.13M |
| Capital expenditures | 1427.48M | 26.64M | 7.44M | 12.75M | 4.39M |
| Change in working capital | 173.78M | -62.57M | 13.15M | 24.91M | -5.06M |
| Stock based compensation | - | 19.33M | 16.14M | 2.76M | 1.57M |
| Other non cash items | 221.14M | -25.25M | 20.32M | -58.48M | -8.47M |
| Free cash flow | 1431.07M | -342.97M | 302.25M | -44.38M | -144.84M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BRCTF BioArctic AB (publ) |
- -% |
29.40 | 26.21 | 357.14 | 13.44 | 13.64 | 13.54 | 20.93 |
| NVO Novo Nordisk A/S |
0.79 2.05% |
39.08 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
14.65 2.77% |
544.34 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.83 0.35% |
813.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
| Name | Title | Year Born |
|---|---|---|
| Dr. Gunilla Osswald Ph.D. | Chief Exec. Officer | 1961 |
| Dr. Pär Gellerfors | Co-Founder, Sr. VP of Bus. Strategy & Director | 1947 |
| Prof. Lars Lannfelt | Co-Founder, Sr. VP of University Collaborations & Director | 1949 |
| Mr. Jan Mattsson | VP of Fin., Sec. of the Board & CFO | 1960 |
| Mr. Christer Möller | VP of Pre-Clinical Devel. & Chief Scientific Officer | 1959 |
| Mr. Oskar Bosson | VP of Communications & IR | 1976 |
| Mr. Harald Borgeke | Head of Public Affairs | NA |
| Ms. Frida Lekander | Head of Marketing | NA |
| Ms. Gunilla Andersson | Sr. Director of HR | 1961 |
| Ms. Johanna Fälting | VP & Head of Research | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...